ESYN EnerSyn Global Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1897245 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-76.8%
TTM net income YoY-391.3%
TTM EPS YoY-244.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin50.7%
Operating margin—
Net margin-2,095.4%
FCF margin-327.6%
EBITDA margin—
Returns
ROE-69.0%
ROA-46.6%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.00x
Current ratio3.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio-39.3%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $866,926 | $1.25M |
| Cost of revenue | $407,199 | $651,721 |
| Gross profit | $459,727 | $601,856 |
| SG&A expense | $3.53M | $2.81M |
| Interest expense | $52,242 | $72,076 |
| Pretax income | -$2.61M | -$2.77M |
| Income tax | $47,472 | — |
| Net income | -$2.63M | -$2.75M |
| EPS (basic) | -0.40 | -0.76 |
| EPS (diluted) | -0.40 | -0.76 |
| Weighted avg. shares (diluted) | 6.56M | 3.61M |
| Balance sheet | ||
| Cash & equivalents | $2.09M | $4.34M |
| Short-term investments | $84,466 | $13,272 |
| Receivables | $3,324 | — |
| Inventory | $1,057 | $1,574 |
| Current assets | $2.97M | $5.47M |
| PP&E, net | $19,153 | $33,588 |
| Goodwill | $116,648 | $0 |
| Total assets | $4.57M | $6.41M |
| Current liabilities | $1.28M | $3.31M |
| Total liabilities | $1.88M | $3.53M |
| Shareholders' equity | $2.62M | $2.77M |
| Shares outstanding | 7.48M | 5.59M |
| Cash flow statement | ||
| Operating cash flow | -$1.75M | -$1.82M |
| Capital expenditure | $19,464 | $30,394 |
| Free cash flow | -$1.77M | -$1.85M |
| Investing cash flow | -$1.19M | $20.45M |
| Financing cash flow | $934,714 | -$15.60M |
| Depreciation & amortization | $19,494 | $48,172 |
| Stock-based compensation | $1.58M | — |
| Share buybacks | — | $21.10M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.